Victrex plc (LON:VCT)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 533.77M |
| Revenue (ttm) | 292.70M |
| Net Income (ttm) | 27.80M |
| Shares Out | 87.07M |
| EPS (ttm) | 0.32 |
| PE Ratio | 19.28 |
| Forward PE | 15.63 |
| Dividend | 0.60 (9.72%) |
| Ex-Dividend Date | Jan 29, 2026 |
| Volume | 179,717 |
| Average Volume | 173,012 |
| Open | 629.00 |
| Previous Close | 627.00 |
| Day's Range | 612.00 - 629.00 |
| 52-Week Range | 515.00 - 935.00 |
| Beta | 0.75 |
| RSI | 47.20 |
| Earnings Date | May 11, 2026 |
About Victrex
Victrex plc, through its subsidiaries, engages in the manufacture and sale of polymer solutions worldwide. The company operates through two segments, Sustainable Solutions and Medical. It develops PEEK and PAEK based polymer solutions, and semi-finished and finished parts. The company also provides specialist solutions for medical device manufacturers; and sells thermoplastic polymers; sustainable solutions for energy and industrial, VAR, aerospace, automotive, and electronics markets, as well as engages in trading activities. It serves automot... [Read more]
Financial Performance
In fiscal year 2025, Victrex's revenue was 292.70 million, an increase of 0.58% compared to the previous year's 291.00 million. Earnings were 27.80 million, an increase of 61.63%.
Financial StatementsNews
Victrex Earnings Call Transcript: H2 2025
FY 2025 saw 12% volume growth but only a 1% revenue rise, with profit hit by currency and mix. A new profit improvement plan targets £10m in savings, while FY 2026 guidance expects modest growth, stable margins, and continued strong cash conversion.
Victrex Earnings Call Transcript: Q3 2025
Q3 saw 8% volume growth but a 3% revenue decline due to adverse mix and medical weakness. Full-year volume guidance remains high single digits, with currency and medical spine headwinds impacting outlook. CEO transition and China facility progress highlighted.
Victrex Earnings Call Transcript: H1 2025
H1 2025 saw 16% volume growth and strong cash conversion, but gross margin and ASP declined due to mix and China ramp-up costs. Full-year guidance was upgraded for volume but lowered for ASP and margin, with strong outlooks in aerospace, electronics, and medical non-spine.
Victrex Earnings Call Transcript: H2 2024
Volumes grew 4% in FY 2024, but revenue fell 5% due to medical destocking and lower asset utilization, leading to a 26% drop in underlying PBT. Strong cash conversion and reduced CapEx position the business for mid-single-digit volume growth and margin improvement in FY 2025.
Victrex Earnings Call Transcript: Q3 2024
Q3 saw 20% volume and 2% revenue growth year-over-year, with strong performance in VAR, electronics, and aerospace, but medical remains a headwind due to industry-wide destocking. Full-year volume growth is expected in the low to mid-single digits, though profit improvement depends on medical recovery.
Victrex Earnings Call Transcript: H1 2024
Victrex Earnings Call Transcript: H2 2023
Victrex Earnings Call Transcript: Q3 2023
Invibio, Part of Victrex plc, Announces New Collaboration With Paragon Medical to Support Scale Up of PEEK Based Trauma Devices
LANCASTER, England--(BUSINESS WIRE)--Invibio establishes composite trauma manufacturing capacity in China, by collaborating with Paragon Medical.
Victrex Earnings Call Transcript: H1 2023
Victrex Has Growth and Value
Victrex PLC ( LSE:VCT , Financial) is a British specialty chemicals company that is a world leader in high-performance polymer solutions.